Bayer HealthCare

Divisions of Bayer HealthCare

• More information about the four divisions of Bayer HealthCare

Sales 2010

Sales of the HealthCare subgroup grew by 5.8 percent in 2010, to € 16,913 million. Adjusted for currency and portfolio effects, sales climbed by 1.7 percent. The increase was due to the positive business performance of both segments.

• Our 20 best-selling products in 2010

Performance 2010

Sales of the Pharmaceuticals segment increased by 4.2% in 2010 to €10,908 million (2009: €10,467 million). Adjusted for currency and portfolio effects, business was up by 0.9%. Sales grew strongly in the Asia / Pacific and Latin America / Africa / Middle East regions but decreased in North America, mainly because of lower sales of yaz® in the United States. Reforms in the statutory health care systems of various countries also had a negative impact on the business.

Sales of the Consumer Health segment advanced by 8.8% in 2010 to €6,005 million (2009: €5,521 million). Business expanded by 3.4% on a currency- and portfolio-adjusted basis, with all regions – particularly North America – contributing to this performance.

In the Consumer Care Division, sales climbed by 9.4% to €3,371 million (2009: €3,080 million). Adjusted for currency and portfolio effects, the increase came to 4.2%. A notable increase in demand for our products in the United States particularly benefited sales of the analgesic Aleve® (Fx adj. +18.7%) and the One A Day® line of dietary supplements (Fx adj. +10.0%). Sales of Aspirin® (Fx adj. +0.2%) were flat with the previous year. Business with the Bepanthen® / Bepanthol® line of skincare products (Fx adj. +12.0%) developed well, especially in Europe and Latin America, thanks to higher volumes and selling prices. Our antifungal Canesten® (Fx adj. +7.7%) advanced, mainly as a result of new product launches in Canada. Sales of Supradyn® multivitamins were level with the prior year (Fx adj. +0.7%).

In the Medical Care Division, sales gained 3.4% to €1,514 million (2009: €1,464 million). On a currency-adjusted basis, business was down by 1.3%. This was chiefly attributable to the negative development of the diabetes care market in the United States, where both prices and volumes declined. Sales of our Breeze® (Fx adj. -13.6%) and Contour® (Fx adj. -4.5%) lines of blood glucose meters were particularly affected. In Europe, however, the Contour® business performed well, due in part to new product launches. Sales of our medical equipment business (Fx adj. +7.2%) showed an overall improvement, particularly in the United States.

Sales of the Animal Health Division climbed by a very satisfactory 14.6% to €1,120 million (2009: €977 million), thanks to the positive development in all regions. After adjusting for currency effects, the increase came to 7.7%. The strongest growth was achieved in North America. Business with the Advantage® line of flea, tick and worm control products (Fx adj. +14.6%) expanded significantly, especially in the United States, where we benefited from the initial stocking and further expansion of a new distribution channel through pet-product retailers. Sales of our Baytril® antibiotic (Fx adj. +5.8%) rose in the United States, while business in Europe was down because of the increasing generic competition.

Research & Development 2010

In 2010 we invested €2,066 million (2009: €1,847 million) in research and development in the Pharmaceuticals and Consumer Health segments. This represented 67.7% of the Bayer Group’s entire research and development expenditures and was equivalent to 12.2% of HealthCare sales.

• More information about Research & Development

More information

 

• The four divisions of Bayer HealthCare
• Our 20 best-selling products in 2010
• More information about Research & Development of our divisions